ATE309215T1 - Nmda (n-methyl-d-aspartate) antagonists - Google Patents

Nmda (n-methyl-d-aspartate) antagonists

Info

Publication number
ATE309215T1
ATE309215T1 AT97938377T AT97938377T ATE309215T1 AT E309215 T1 ATE309215 T1 AT E309215T1 AT 97938377 T AT97938377 T AT 97938377T AT 97938377 T AT97938377 T AT 97938377T AT E309215 T1 ATE309215 T1 AT E309215T1
Authority
AT
Austria
Prior art keywords
nmda
aspartate
antagonists
methyl
Prior art date
Application number
AT97938377T
Other languages
English (en)
Inventor
Boyd L Harrison
Raymond S Gross
Bruce M Baron
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Application granted granted Critical
Publication of ATE309215T1 publication Critical patent/ATE309215T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT97938377T 1996-09-30 1997-08-18 Nmda (n-methyl-d-aspartate) antagonists ATE309215T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72317596A 1996-09-30 1996-09-30
PCT/US1997/014486 WO1998014427A1 (en) 1996-09-30 1997-08-18 Nmda (n-methyl-d-aspartate) antagonists

Publications (1)

Publication Number Publication Date
ATE309215T1 true ATE309215T1 (de) 2005-11-15

Family

ID=24905175

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97938377T ATE309215T1 (de) 1996-09-30 1997-08-18 Nmda (n-methyl-d-aspartate) antagonists

Country Status (18)

Country Link
EP (1) EP0929521B1 (de)
JP (1) JP2001501221A (de)
KR (1) KR20000048715A (de)
CN (1) CN1139572C (de)
AR (1) AR009374A1 (de)
AT (1) ATE309215T1 (de)
AU (1) AU732997B2 (de)
BR (1) BR9712144A (de)
CA (1) CA2266556C (de)
DE (1) DE69734594T2 (de)
DK (1) DK0929521T3 (de)
HU (1) HUP0000882A3 (de)
IL (1) IL129187A0 (de)
NO (1) NO314080B1 (de)
NZ (1) NZ334343A (de)
TW (1) TW492958B (de)
WO (1) WO1998014427A1 (de)
ZA (1) ZA978602B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010053849A1 (en) * 1999-06-16 2001-12-20 Mary Jeanne Kreek Plural biological sample arrays, and preparation and uses thereof
KR20030060771A (ko) 2000-04-28 2003-07-16 메모리얼 슬로안-케터링 캔서 센터 국소용 마취제/아편양약물 제제 및 이들의 용도
HU227197B1 (en) 2000-10-24 2010-10-28 Richter Gedeon Nyrt Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them
US7820688B2 (en) 2001-04-27 2010-10-26 Memorial Sloan-Kettering Cancer Center Topical anesthetic/opioid formulations and uses thereof
WO2003039540A2 (en) * 2001-11-09 2003-05-15 Sepracor Inc. D-amino acid oxidase inhibitors for learning and memory
DE10306202A1 (de) 2003-02-13 2004-08-26 Grünenthal GmbH Arzneimittel enthaltend substituierte 2-Aryl-Aminoessigsäure-Verbindungen und/oder substituierte 2-Heteroaryl-Aminoessigsäure-Verbindungen
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
AU2008315651B2 (en) * 2007-10-22 2012-12-13 Orchid Research Laboratories Limited Histone deacetylase inhibitors
KR20120123089A (ko) 2010-02-16 2012-11-07 화이자 인코포레이티드 5-ＨＴ₄ 수용체의 부분 효능제인 (Ｒ)-4-((4-((4-(테트라히드로푸란-3-일옥시)벤조［ｄ］이속사졸-3-일옥시)메틸)피페리딘-1-일)메틸)테트라히드로-2Ｈ-피란-4-올
CA3146163A1 (en) 2019-07-08 2021-01-14 University Of Health Sciences & Pharmacy In St. Louis G-protein biased opioid receptor agonist/analgesics with reduced arrestin recruitment
CN121695288A (zh) 2020-02-19 2026-03-20 Epizyme股份有限公司 Setd2抑制剂和相关方法和用途，包括组合疗法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU216787B (hu) * 1990-07-16 1999-08-30 Merrell Dow Pharmaceuticals Inc. Eljárás excitátoros aminosav-antagonista hatású indolszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
GB9208492D0 (en) * 1992-04-16 1992-06-03 Glaxo Spa Heterocyclic compounds
US5519048A (en) * 1993-05-27 1996-05-21 Merrell Pharmaceuticals Inc. 3-(indol-3-yl)-propenoic acid derivatives and pharmaceutical compositions thereof
WO1994027964A1 (en) * 1993-05-27 1994-12-08 Merrell Dow Pharmaceuticals Inc. 3-(indol-3-yl) propenoic acid derivatives and as nmda antagonists
GB9319243D0 (en) * 1993-09-17 1993-11-03 Glaxo Spa Heterocyclic compounds

Also Published As

Publication number Publication date
AU732997B2 (en) 2001-05-03
EP0929521B1 (de) 2005-11-09
TW492958B (en) 2002-07-01
CA2266556A1 (en) 1998-04-09
EP0929521A1 (de) 1999-07-21
AR009374A1 (es) 2000-04-12
WO1998014427A1 (en) 1998-04-09
AU4071897A (en) 1998-04-24
HUP0000882A3 (en) 2001-04-28
NO991533D0 (no) 1999-03-29
DK0929521T3 (da) 2006-03-27
ZA978602B (en) 1998-03-30
NO991533L (no) 1999-05-28
IL129187A0 (en) 2000-02-17
NO314080B1 (no) 2003-01-27
DE69734594D1 (en) 2005-12-15
CN1139572C (zh) 2004-02-25
NZ334343A (en) 2001-01-26
HUP0000882A2 (hu) 2000-09-28
CN1232452A (zh) 1999-10-20
CA2266556C (en) 2007-11-06
JP2001501221A (ja) 2001-01-30
KR20000048715A (ko) 2000-07-25
BR9712144A (pt) 1999-08-31
DE69734594T2 (de) 2006-07-06

Similar Documents

Publication Publication Date Title
DK1009732T3 (da) 1-Amino-alkylcyclohexan NMDA receptor antagonister
ATE214382T1 (de) Östrogen-agonisten/antagonisten
EE9600186A (et) Neurokiniini (tahhüülkiniini) antagonistid
DE69830854D1 (de) Mehrfaches testverfahren
NL1008254A1 (nl) Testinrichtingen.
EP0986385A4 (de) Antagonisten des gonadorelins
DE69622751D1 (de) Arbeitsplatz
FI971026A7 (fi) Kinoksaliinidioni-NMDA-reseptoriantagonisteja
DE69726660D1 (de) Projektionsvorrichtung
FI960516A7 (fi) Substituoituja bifenyylisulfonamidiendoteliiniantagonisteja
DK0854867T3 (da) Tetrahydroquinoliner som NMDA-antagonister
DK0929521T3 (da) NMDA-antagonister (N-methyl-D-aspartat-antagnonister)
FI920880A7 (fi) NMDA-antagonisteja
FI933762L (fi) Nmda antagonister
ATE116653T1 (de) Nmda-antagonisten.
KR970702876A (ko) 뉴로키닌 길항제(Neurokinine (tachykinine) antagonists)
KR950027351U (ko) 반목 항타장치
KR970002813U (ko) 각도가 있는 컴퓨터용 마우스 판
SE9700316D0 (sv) Strömmätare
KR960006324U (ko) 프로빙 시간단축 쏘소자
KR970047433U (ko) 어댑터
FI974114A0 (fi) Skorstenshatt (regntak)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0929521

Country of ref document: EP

REN Ceased due to non-payment of the annual fee